You are currently viewing Hair Restoration Advancements: 2026 Data

Hair Restoration Advancements: 2026 Data

Hair restoration is advancing on two fronts: FUE dominates surgical treatment, while nonsurgical care continues to grow. In 2024, members of the International Society of Hair Restoration Surgery (ISHRS) used FUE harvesting in 85.4% of male cases. The average member treated 498 non-surgical patients, up from 396 in 2021.

Cosmo Pharmaceuticals tested clascoterone 5%, a new topical drug, in two Phase 3 trials involving 1,465 men and reported up to a 539% relative increase in hair count compared with placebo. Use the four breakdowns below to see how findings relate to your gender, treatment path, and hair restoration goals.

Key Takeaways

  • FUE share: ISHRS members used FUE harvesting in 85.4% of male cases and 68.2% of female cases in 2024.
  • Finasteride: 72.3% of ISHRS members prescribed finasteride 1 mg always or often, the highest rate of any therapy.
  • Oral minoxidil: 64.7% of members prescribed oral minoxidil always or often, compared with 55.3% for topical minoxidil.
  • Female patients: Surgical patients rose by 16.5% from 2021 to 2024.

Formulas Behind the Figures

Most figures on this page come from the ISHRS 2025 Practice Census, a survey of ISHRS member physicians. We calculated patient volume changes with the formula below.

Metric Formula
Percent Change (2024 value − 2021 value) ÷ 2021 value × 100
Always or Often Prescribed Rate Members who answered “always” or “often” ÷ all responding members × 100
Relative Gain vs. Placebo Hair count gain in the treatment group compared with the gain in the placebo group, as reported by the trial sponsor

Key Insights

  • Percent change: Non-surgical patients per member rose from 396 to 498, a 25.8% increase by this formula.
  • Prescribing rate: A 72.3% rate for finasteride means about 7 in 10 responding ISHRS members prescribe it always or often.
  • Relative gain: Cosmo Pharmaceuticals reports the 539% and 168% clascoterone figures as relative results and has yet to publish absolute hair counts.

FUE Harvesting Share by Patient Gender (2024)

ISHRS members reported the harvesting method they used for male and female transplant patients in 2024. In FUE, the surgeon removes grafts one at a time. In follicular unit transplantation (FUT), the surgeon removes a thin strip of donor scalp.

Harvest Method Male Patients Female Patients
FUE Harvesting 85.4% 68.2%
FUT (Strip) Harvesting 12.5% 30.0%
Combination of FUE and FUT 2.1% 1.9%

Key Insights

  • Male patients: FUE accounted for 85.4% of male cases, nearly 7 times the FUT share of 12.5%.
  • Female patients: Surgeons chose FUT for 30.0% of female cases, more than double the male rate.
  • Graft counts: The mean FUE case used 2,262 grafts and the mean FUT case used 2,100 grafts, a difference of 162 grafts.

Medical Therapies ISHRS Members Prescribe Most (2024)

ISHRS asked members how often they prescribe or recommend each non-surgical therapy. The table lists the share of members who answered “always” or “often”.

Therapy Members Prescribing Always or Often
Finasteride 1 mg (Oral) 72.3%
Minoxidil (Oral) 64.7%
Minoxidil (Topical, 2% or 5%) 55.3%
Platelet-Rich Plasma (PRP) 49.8%
Dutasteride (Oral) 36.7%
Low-Level Laser Therapy (LLLT), In-Office 31.2%

Key Insights

  • Finasteride: 72.3% of members prescribe finasteride always or often, the top rate on the list.
  • Oral minoxidil: Members prescribe oral minoxidil 9.4 percentage points more often than topical minoxidil.
  • PRP: Roughly half of members (49.8%) recommend PRP always or often.

Clascoterone and Oral Minoxidil Trial Results

Researchers recently tested two medical options for men with androgenetic alopecia (AGA), also called male pattern hair loss. Dermatology Times reported the clascoterone results from Cosmo Pharmaceuticals, and JAMA Dermatology published the oral minoxidil trial.

Trial Participants Timepoint Reported Result
Clascoterone 5%, SCALP 1 1,465 men across both trials 6 months 539% relative gain in target-area hair count vs. placebo
Clascoterone 5%, SCALP 2 1,465 men across both trials 6 months 168% relative gain in target-area hair count vs. placebo
Clascoterone 5%, Continued Use 1,465 men across both trials 12 months 2.39× the hair count gain of men switched to placebo at 6 months
Oral Minoxidil 5 mg vs. Topical Minoxidil 5% 68 men 24 weeks 70% vs. 46% showed crown (vertex) improvement in photos

In the minoxidil trial, the oral and topical groups reached statistically similar overall hair density.

Key Insights

  • Clascoterone satisfaction: Men who stayed on clascoterone for 12 months reported 24.5% higher treatment satisfaction than men switched to placebo.
  • Clascoterone timeline: Cosmo plans to file with the U.S. Food and Drug Administration (FDA) in early 2027, so clascoterone 5% remains unapproved for hair loss in 2026.
  • Oral minoxidil side effects: 49% of oral minoxidil users developed unwanted body or facial hair (hypertrichosis), compared with 25% of topical users.

Patient Volume Changes, 2021 vs. 2024

ISHRS compared average patient counts and case types per member between 2021 and 2024. We calculated the percent changes with the formula above.

Metric 2021 2024 Change
Surgical Patients per Member 165 156 −5.5%
Non-Surgical Patients per Member 396 498 +25.8%
Men Seeking Non-Scalp Procedures 13% 18% +5 points
Women Seeking Non-Scalp Procedures 17% 21% +4 points
Repair Cases Linked to Black-Market Transplants 6% 10% +4 points

Key Insights

  • Medical care: The average member gained 102 non-surgical patients and lost 9 surgical patients between 2021 and 2024.
  • Non-scalp procedures: Eyebrow work accounted for 12% of female non-scalp procedures, and beard or mustache work accounted for 5% of male non-scalp procedures.
  • Black-market clinics: 59% of ISHRS members reported black-market clinics in their cities in 2024, up from 51% in 2021.

Request a PDF Copy of This Report

To get a PDF copy of this report, contact the Center for Hair Transplantation.

Further Reading

Sources